Cytochromes P450 polymorphisms

Vermes A et al. Individualisation of cancer therapy based on cytochrome P450 polymorphism a pharmacogenetic approach. Cancer Treat Rev 1997 23 321-339. 

Yamada, H., Dahl, M.L., Viitanen, M., Winblad, B., Sjoqvist, E., Lannfelt, L. (1998) No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Dis. Assoc. Disord., 12, 204-207. 

Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics translating functional genomics into rational therapeutics. Science, 286, 487—4-91. Wijnen, P.A. et cd. (2007) Review article. The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment. Pharmacol. Then, 26 (Suppl 2), 211-219. 

Brockmoller J, Kirchheiner J, Meisel C, etal. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000 1 125-151. 

Zordoky BN, El-Kadi AO (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125 446 63... 

Aithal, G.P., Day, C.P., and Kesteven, P.J. et al. (1999). Association of polymorphisms in the cytochrome P450 C YP2C9 with warfarin dose requirement and risk of bleeding comph-cations. Lancet 353, 717-719. 

Carrillo, J. A. et al. (2003). Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. /. Clin. Psychopharmacol., 23, 119-27. 

Chen, J., Lu, Z., Jiang, S. D. et al. (2005). Association between polymorphism in the cytochrome P450 enzymes 1A2 2C19 gene and treatment-resistant depression. Shanghai Archive of Psychiatry, 17(2), 95-8. 

Huang, Y., Liu, X. H., Xu, K. et al. (2002b). Association study of cytochrome P450 2D6 gene polymorphism and therapeutic response to risperidone in Chinese subjects with schizophrenia. Journal of Chinese Psychiatry, 35(2), 103-6. 

Zhang, S., Dong, Z. W., Tang, L. et al. (2002). Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations. Journal of Chinese Medical Genetics, 19(1), 52 4. 

Luo, H. R., Poland, R., Lin, K. M. Wan, Y. Y. (2006). Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans a cross ethnic comparative study. Clin. Pharmacol. Ther., 80, 33-40. 

Ingelman-Sundberg M, Oscarson M, McLelian RA. Polymorphic human cytochrome P450 enzymes an opportunity for individualized dmg treatment. Trends Pharmacol Sci 1999 20 342-349. 

It has now been established that genetic polymorphisms in drug metabolizing enzymes such as the cytochrome P450s (CYP) and the phase II enzyme, thiopu-rine methyltransferase, are responsible for inter-individual variability in response and adverse reactions [12, 13]. However, at the present time, the impact of poly-... 

Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C—>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999 47(4) 445—449. 

Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001 105(6) 498-501. 

Bertilsson, L., "Geographical/Interracial Differences in Polymorphic Drag Oxidation Current State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19," Clin. Pharmacokinet., 29, 192-209 (1995). 

---